Latest News

July 2021

Multiple research reports have been published in the last month on the global CRO market:

1. https://www.globenewswire.com/news-release/2021/06/30/2255741/0/en/Global-Pharmaceutical-Contract-Manufacturing-Contract-Market-Size-2021-Covid-19-Impact-Analysis-by-Future-Demands-Growth-Factors-Trends-Emerging-Technologies-Prominent-Players-Futu.html

2. https://www.prnewswire.com/news-releases/global-contract-research-outsourcing-market-to-reach-67-1-billion-by-2026--301319901.html

3. https://www.businesswire.com/news/home/20210616005393/en

4. https://www.prnewswire.com/news-releases/global-contract-research-organization-cro-market-report-2021-increased-focus-on-patient-centricity-and-diversity-in-clinical-trials-provide-growth-opportunities-for-cros-and-technology-vendors-301308009.html

5. https://www.europeanpharmaceuticalreview.com/news/156863/global-clinical-trials-market-to-value-77-billion-by-2026/

How the COVID-19 pandemic has brought about explosive change in adoption of digital technologies, and its lasting effect on life sciences:


Contract research organizations were hit last year as the COVID-19 pandemic disrupted clinical trials, but they are now seeing a resurgence in demand as drugmakers and governments invest in newer treatments:


Scientists are on the hunt for a universal vaccine that will protect against not only SARS-CoV-2, but other members of its family that may emerge in the future. One candidate is already in a Phase 1 clinical trial:


Nearly 6,000 clinical trial results are currently missing from the European trial registry, despite transparency rules requiring countries to upload results within 12 months of trial completion:


Medical researchers are beginning to shift their focus away from COVID-19 — but the pandemic could continue to affect clinical trials focused on other diseases:


A new study suggests that significant variation in the amount of virus from person to person may be a contributing factor to inconsistent findings reported in clinical trials for antiviral COVID-19 drugs:


COVID-19 affects men and women differently. So why don’t clinical trials report gender data?


AstraZeneca’s proposed $39billion acquisition of Alexion Pharmaceuticals has cleared its European Commission review. It follows competition clearances in the United States, Japan and a number of other countries around the world, but regulatory clearance in the UK is pending:


Practical actions for consideration to increase diversity in clinical trials - by Dr Esther Mukuka, National Institute for Health Research (NIHR) Head of Equality, Diversity and Inclusion:


Oracle Partner NCC Group

Customer Area